Immunotherapy-Based Combinations Remain the Focus of Frontline Treatment in Metastatic RCC
October 20th 2022Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.
Read More
Uproleselan Plus Chemotherapy Could Provide MRD Benefit in Relapsed/Refractory AML
October 17th 2022Although the exact role of minimal residual disease in patients with acute myeloid leukemia requires further definition, MRD status could help provide a clearer pathway for treatment decisions in this patient population.
Read More
Dinutuximab Plus GM-CSF Does Not Improve DCR in Recurrent Osteosarcoma
October 16th 2022R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.
Read More
Evolving Knowledge of BTK Inhibitors Continues to Shape Treatment Landscape in CLL
October 14th 2022Jonathon B. Cohen MD, MS, discusses the management of chronic lymphocytic leukemia with BTK inhibitors, updates in the treatment of acute myeloid leukemia, and how CAR T-cell therapy could improve patient outcomes in diffuse large B-cell lymphoma and mantle cell lymphoma.
Read More
Targeted Therapy Combinations Provide Multiple Treatment Options in BRAF-Mutated Melanoma
October 12th 2022Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.
Read More
González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.
Read More
Dostarlimab Elicits Survival Benefit in dMMR/MSI-H Advanced Endometrial Cancer
October 11th 2022Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.
Read More
Frontline Avelumab Maintenance Displays Long-Term Benefit in Advanced Urothelial Carcinoma
October 10th 2022Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.
Read More
Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML
October 9th 2022Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.
Read More
Neoadjuvant Radioimmunotherapy Demonstrates Feasibility in Locally Advanced Urothelial Carcinoma
October 7th 2022Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.
Read More
Durvalumab, Tremelimumab, and Chemotherapy Elicit Promising Long-Term OS Rates in NSCLC
October 6th 2022Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.
Read More
Patient-Reported Outcomes Support Use of Trastuzumab Deruxtecan in HR+/HER2-Negative Breast Cancer
October 6th 2022Fam-trastuzumab deruxtecan-nxki preserved quality of life vs physicians choice of treatment in patients with advanced, hormone receptor–positive/HER2-low metastatic breast cancer.
Read More
Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL
October 3rd 2022Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Sunvozertinib Generates Responses in Platinum-Pretreated EGFR Exon 20–Mutated NSCLC
September 27th 2022Sunvozertinib provided beneficial antitumor activity when used as a second- or later-line treatment in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy.
Read More
Fruquintinib Provides Significant Survival Benefits in Heavily Pretreated mCRC
September 26th 2022Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.
Read More
Frontline Immunotherapy Combos Linked With Higher CR Rates Than Anti-VEGF Therapy in mRCC
September 20th 2022Immunotherapy-based combinations elicited higher complete response rates compared with VEGF-targeted therapy when used as first-line treatment in patients with metastatic renal cell carcinoma.
Read More
Surgical Complications Unrelated to Timing of Neoadjuvant Chemotherapy in Lower-Extremity Sarcomas
September 6th 2022R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.
Read More
Social Determinants and Genetics Work in Tandem to Drive Disparities in Breast Cancer Care
September 2nd 2022Adana A.M. Llanos, PhD, MPH, discusses key research on the social and biological factors that influence disparities in breast cancer, how these factors work in tandem to affect patient outcomes, and how this knowledge can be deployed in the real world.
Read More
Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL
September 2nd 2022Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.
Read More
SEL24/MEN1703 Demonstrates Early Efficacy, Tolerability in R/R AML With IDH1/2 Mutations
September 1st 2022The first-in-class dual PIM/FLT3 kinase inhibitor, SEL24/MEN1703, showcased encouraging efficacy and a tolerable safety profile in patients with acute myeloid leukemia whose tumors harbor a IDH1/2 mutation.
Read More
Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma
September 1st 2022Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.
Read More